News Releases
View printer-friendly version < < backNet earnings** and diluted earnings per share for the third quarter of 2012 were
"Our third-quarter results reflected continued sales momentum driven by strong growth of key products, successful new product launches, and the addition of Synthes to our family of companies. We advanced our pipelines with regulatory approvals for a number of new products, the submission of several new drug applications, and the completion of several strategic collaborations," said
The Company updated its earnings guidance for full-year 2012 to
Worldwide Consumer sales of
Positive contributors to operational results were sales of upper respiratory over-the-counter products; international sales of LISTERINE® oral care products; and NEUTROGENA® skin care products.
Worldwide Pharmaceutical sales of
Primary contributors to operational sales growth were REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases; PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and a number of recently launched products.
The strong sales results of recently launched products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone, for the treatment of metastatic, castration-resistant prostate cancer; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; international sales of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults; XARELTO® (rivaroxaban), an oral anticoagulant; and SIMPONI®(golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Sales results were negatively impacted by the manufacturing suspension at a third-party supplier for DOXIL® (doxorubicin HCl liposome injection)/CAELYX® (pegylated liposomal doxorubicin hydrochloride), a medication to treat ovarian and other cancers.
During the quarter, the
Also during the quarter, a Biologics License Application was submitted to the
In August, a Marketing Authorization Application was submitted to the EMA seeking conditional approval for the use of bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis in adults.
In October, a license agreement was entered into with Astellas Pharma Inc. for the worldwide development and commercialization, except in
Worldwide Medical Devices and Diagnostics sales of
Primary contributors to operational growth were sales from the recently completed acquisition of
During the quarter,
About
Caring for the world, one person at a time…inspires and unites the people of
* Net earnings** and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.
** Net earnings attributable to
NOTE TO INVESTORS
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, condensed consolidated statements of earnings, and sales of key products/franchises. Additional information on
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of
business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
THIRD QUARTER |
NINE MONTHS | |||||||||||||||||
Percent Change |
Percent Change | ||||||||||||||||||
2012 |
2011 |
Total |
Operations |
Currency |
2012 |
2011 |
Total |
Operations |
Currency | ||||||||||
Sales to customers by |
|||||||||||||||||||
segment of business |
|||||||||||||||||||
Consumer |
|||||||||||||||||||
U.S. |
$ 1,214 |
1,219 |
(0.4) |
% |
(0.4) |
- |
$ 3,843 |
3,903 |
(1.5) |
% |
(1.5) |
- | |||||||
International |
2,367 |
2,521 |
(6.1) |
1.8 |
(7.9) |
6,952 |
7,312 |
(4.9) |
1.4 |
(6.3) | |||||||||
3,581 |
3,740 |
(4.3) |
1.0 |
(5.3) |
10,795 |
11,215 |
(3.7) |
0.4 |
(4.1) | ||||||||||
Pharmaceutical |
|||||||||||||||||||
U.S. |
3,288 |
2,869 |
14.6 |
14.6 |
- |
9,408 |
9,499 |
(1.0) |
(1.0) |
- | |||||||||
International |
3,114 |
3,113 |
0.0 |
8.2 |
(8.2) |
9,418 |
8,775 |
7.3 |
14.1 |
(6.8) | |||||||||
6,402 |
5,982 |
7.0 |
11.3 |
(4.3) |
18,826 |
18,274 |
3.0 |
6.3 |
(3.3) | ||||||||||
Med Devices & Diagnostics |
|||||||||||||||||||
U.S. |
3,289 |
2,780 |
18.3 |
18.3 |
- |
9,119 |
8,521 |
7.0 |
7.0 |
- | |||||||||
International |
3,780 |
3,503 |
7.9 |
14.4 |
(6.5) |
10,926 |
10,765 |
1.5 |
6.2 |
(4.7) | |||||||||
7,069 |
6,283 |
12.5 |
16.1 |
(3.6) |
20,045 |
19,286 |
3.9 |
6.5 |
(2.6) | ||||||||||
U.S. |
7,791 |
6,868 |
13.4 |
13.4 |
- |
22,370 |
21,923 |
2.0 |
2.0 |
- | |||||||||
International |
9,261 |
9,137 |
1.4 |
8.9 |
(7.5) |
27,296 |
26,852 |
1.7 |
7.5 |
(5.8) | |||||||||
Worldwide |
$ 17,052 |
16,005 |
6.5 |
% |
10.8 |
(4.3) |
$ 49,666 |
48,775 |
1.8 |
% |
5.0 |
(3.2) |
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
THIRD QUARTER |
NINE MONTHS | |||||||||||||||||
Percent Change |
Percent Change | ||||||||||||||||||
2012 |
2011 |
Total |
Operations |
Currency |
2012 |
2011 |
Total |
Operations |
Currency | ||||||||||
Sales to customers by |
|||||||||||||||||||
geographic area |
|||||||||||||||||||
U.S. |
$ 7,791 |
6,868 |
13.4 |
% |
13.4 |
- |
|
21,923 |
2.0 |
% |
2.0 |
- | |||||||
|
3,983 |
4,124 |
(3.4) |
7.1 |
(10.5) |
12,342 |
12,850 |
(4.0) |
4.2 |
(8.2) | |||||||||
Western Hemisphere excluding U.S. |
1,824 |
1,751 |
4.2 |
12.8 |
(8.6) |
5,266 |
4,730 |
11.3 |
19.1 |
(7.8) | |||||||||
|
3,454 |
3,262 |
5.9 |
9.0 |
(3.1) |
9,688 |
9,272 |
4.5 |
6.1 |
(1.6) | |||||||||
International |
9,261 |
9,137 |
1.4 |
8.9 |
(7.5) |
27,296 |
26,852 |
1.7 |
7.5 |
(5.8) | |||||||||
Worldwide |
|
16,005 |
6.5 |
% |
10.8 |
(4.3) |
|
48,775 |
1.8 |
% |
5.0 |
(3.2) |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
THIRD QUARTER | ||||||||
2012 |
2011 |
Percent | |||||||
Percent |
Percent |
Increase | |||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) | |||||
Sales to customers |
|
100.0 |
|
100.0 |
6.5 | ||||
Cost of products sold |
5,597 |
32.8 |
5,072 |
31.7 |
10.4 | ||||
Selling, marketing and administrative expenses |
5,228 |
30.6 |
5,240 |
32.7 |
(0.2) | ||||
Research and development expense |
1,923 |
11.3 |
1,773 |
11.1 |
8.5 | ||||
In-process research and development |
679 |
4.0 |
- |
- |
|||||
Interest (income) expense, net |
120 |
0.7 |
117 |
0.7 |
|||||
Other (income) expense, net |
(90) |
(0.5) |
(308) |
(1.9) |
|||||
Earnings before provision for taxes on income |
3,595 |
21.1 |
4,111 |
25.7 |
(12.6) | ||||
Provision for taxes on income |
966 |
5.7 |
909 |
5.7 |
6.3 | ||||
Net earnings |
2,629 |
15.4 |
3,202 |
20.0 |
(17.9) | ||||
Add: Net loss attributable to noncontrolling interest |
339 |
2.0 |
- |
- |
|||||
Net earnings attributable to |
$ 2,968 |
17.4 |
$ 3,202 |
20.0 |
(7.3) | ||||
Net earnings per share attributable to |
$ 1.05 |
$ 1.15 |
(8.7) | ||||||
Average shares outstanding (Diluted) |
2,818.1 |
2,778.2 |
|||||||
Effective tax rate |
26.9 |
% |
22.1 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings |
|||||||||
attributable to |
|||||||||
Earnings before provision for taxes on income |
$ 4,525 |
26.5 |
$ 4,427 |
27.7 |
2.2 | ||||
Net earnings attributable to |
$ 3,521 |
20.6 |
$ 3,443 |
21.5 |
2.3 | ||||
Net earnings per share attributable to Johnson & |
$ 1.25 |
$ 1.24 |
0.8 | ||||||
Effective tax rate |
22.2 |
% |
22.2 |
% |
|||||
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
NINE MONTHS | ||||||||
2012 |
2011 |
Percent | |||||||
Percent |
Percent |
Increase | |||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) | |||||
Sales to customers |
|
100.0 |
|
100.0 |
1.8 | ||||
Cost of products sold |
15,655 |
31.5 |
15,022 |
30.8 |
4.2 | ||||
Selling, marketing and administrative expenses |
15,208 |
30.6 |
15,511 |
31.8 |
(2.0) | ||||
Research and development expense |
5,334 |
10.7 |
5,393 |
11.0 |
(1.1) | ||||
In-process research and development |
1,108 |
2.2 |
- |
- |
|||||
Interest (income) expense, net |
379 |
0.8 |
332 |
0.7 |
|||||
Other (income) expense, net |
1,307 |
2.7 |
(115) |
(0.2) |
|||||
Restructuring expense |
- |
- |
589 |
1.2 |
|||||
Earnings before provision for taxes on income |
10,675 |
21.5 |
12,043 |
24.7 |
(11.4) | ||||
Provision for taxes on income |
2,728 |
5.5 |
2,589 |
5.3 |
5.4 | ||||
Net earnings |
7,947 |
16.0 |
9,454 |
19.4 |
(15.9) | ||||
Add: Net loss attributable to noncontrolling interest |
339 |
0.7 |
- |
- |
|||||
Net earnings attributable to |
$ 8,286 |
16.7 |
$ 9,454 |
19.4 |
(12.4) | ||||
Net earnings per share attributable to |
$ 2.96 |
$ 3.40 |
(12.9) | ||||||
Average shares outstanding (Diluted) |
2,805.0 |
2,777.6 |
|||||||
Effective tax rate |
25.6 |
% |
21.5 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings |
|||||||||
attributable to |
|||||||||
Earnings before provision for taxes on income |
|
28.4 |
|
28.1 |
2.9 | ||||
Net earnings attributable to |
|
22.1 |
|
22.0 |
2.2 | ||||
Net earnings per share attributable to |
$ 3.91 |
$ 3.87 |
1.0 | ||||||
Effective tax rate |
22.2 |
% |
21.6 |
% |
|||||
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|||||||||||||
Reconciliation of Non-GAAP Financial Measures |
|||||||||||||
Third Quarter |
% Incr. / |
Nine Months YTD |
% Incr. / |
||||||||||
(Dollars in Millions Except Per Share Data) |
2012 |
2011 |
(Decr.) |
2012 |
2011 |
(Decr.) |
|||||||
Earnings before provision for taxes on income - as reported |
|
4,111 |
(12.6) |
% |
|
|
(11.4) |
% | |||||
Intangible asset write-downs/adjustments |
(30) |
- |
909 |
- |
|||||||||
Net litigation |
- |
- |
669 |
576 |
|||||||||
Synthes integration/transaction costs and currency related |
165 |
(1) |
316 |
622 |
214 |
||||||||
In-process research and development |
679 |
- |
1,108 |
- |
|||||||||
Restructuring - Cordis |
- |
- |
- |
676 |
|||||||||
DePuy ASR™Hip related costs |
116 |
- |
116 |
187 |
|||||||||
Earnings before provision for taxes on income - as adjusted |
|
4,427 |
2.2 |
% |
|
13,696 |
2.9 |
% | |||||
Net Earnings attributable to |
|
3,202 |
(7.3) |
% |
$ 8,286 |
9,454 |
(12.4) |
% | |||||
Intangible asset write-downs |
(16) |
- |
701 |
- |
|||||||||
Net litigation |
- |
- |
611 |
444 |
|||||||||
Synthes integration/transaction costs and currency related |
135 |
241 |
593 |
139 |
|||||||||
In-process research and development |
340 |
(2) |
- |
684 |
- |
||||||||
Restructuring - Cordis |
- |
- |
- |
549 |
|||||||||
DePuy ASR™Hip related costs |
94 |
- |
94 |
152 |
|||||||||
Net Earnings attributable to |
|
3,443 |
2.3 |
% |
|
10,738 |
2.2 |
% | |||||
Diluted Net Earnings per share attributable to |
$ 1.05 |
1.15 |
(8.7) |
% |
$ 2.96 |
3.40 |
(12.9) |
% | |||||
Intangible asset write-downs |
(0.01) |
- |
0.25 |
- |
|||||||||
Net litigation |
- |
- |
0.22 |
0.16 |
|||||||||
Synthes integration/transaction costs and currency related |
0.05 |
0.09 |
0.21 |
0.05 |
|||||||||
In-process research and development |
0.13 |
- |
0.24 |
- |
|||||||||
Restructuring - Cordis |
- |
- |
- |
0.20 |
|||||||||
DePuy ASR™Hip related costs |
0.03 |
- |
0.03 |
0.06 |
|||||||||
Diluted Net Earnings per share attributable to |
$ 1.25 |
1.24 |
0.8 |
% |
$ 3.91 |
3.87 |
1.0 |
% | |||||
(1) Represents inventory step-up recorded in cost of products sold |
|||||||||||||
(2) In-process research and development of |
|||||||||||||
The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations. | |||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||
THIRD QUARTER |
NINE MONTHS | ||||||||||
% Change |
% Change | ||||||||||
2012 |
2011 |
Reported |
Operational (1) |
Currency |
2012 |
2011 |
Reported |
Operational (1) |
Currency | ||
CONSUMER SEGMENT (2) |
|||||||||||
|
|||||||||||
US |
$ 104 |
105 |
-1.0% |
-1.0% |
- |
$ 309 |
315 |
-1.9% |
-1.9% |
- | |
|
460 |
508 |
-9.4% |
-2.1% |
-7.3% |
1,373 |
1,457 |
-5.8% |
0.3% |
-6.1% | |
WW |
564 |
613 |
-8.0% |
-1.9% |
-6.1% |
1,682 |
1,772 |
-5.1% |
-0.1% |
-5.0% | |
ORAL CARE |
|||||||||||
US |
162 |
162 |
0.0% |
0.0% |
- |
476 |
483 |
-1.4% |
-1.4% |
- | |
|
251 |
260 |
-3.5% |
4.7% |
-8.2% |
732 |
729 |
0.4% |
7.1% |
-6.7% | |
WW |
413 |
422 |
-2.1% |
3.0% |
-5.1% |
1,208 |
1,212 |
-0.3% |
3.7% |
-4.0% | |
OTC/NUTRITIONALS |
|||||||||||
US |
351 |
332 |
5.7% |
5.7% |
- |
1,068 |
1,059 |
0.8% |
0.8% |
- | |
|
709 |
722 |
-1.8% |
6.0% |
-7.8% |
2,128 |
2,207 |
-3.6% |
2.5% |
-6.1% | |
WW |
1,060 |
1,054 |
0.6% |
5.9% |
-5.3% |
3,196 |
3,266 |
-2.1% |
2.0% |
-4.1% | |
|
|||||||||||
US |
390 |
376 |
3.7% |
3.7% |
- |
1,314 |
1,251 |
5.0% |
5.0% |
- | |
|
514 |
567 |
-9.3% |
-2.2% |
-7.1% |
1,410 |
1,520 |
-7.2% |
-1.4% |
-5.8% | |
WW |
904 |
943 |
-4.1% |
0.2% |
-4.3% |
2,724 |
2,771 |
-1.7% |
1.5% |
-3.2% | |
WOMEN'S HEALTH |
|||||||||||
US |
81 |
104 |
-22.1% |
-22.1% |
- |
254 |
350 |
-27.4% |
-27.4% |
- | |
|
326 |
354 |
-7.9% |
2.3% |
-10.2% |
964 |
1,044 |
-7.7% |
0.2% |
-7.9% | |
WW |
407 |
458 |
-11.1% |
-3.2% |
-7.9% |
1,218 |
1,394 |
-12.6% |
-6.7% |
-5.9% | |
WOUND CARE/OTHER |
|||||||||||
US |
126 |
140 |
-10.0% |
-10.0% |
- |
422 |
445 |
-5.2% |
-5.2% |
- | |
|
107 |
110 |
-2.7% |
4.5% |
-7.2% |
345 |
355 |
-2.8% |
3.0% |
-5.8% | |
WW |
233 |
250 |
-6.8% |
-3.6% |
-3.2% |
767 |
800 |
-4.1% |
-1.5% |
-2.6% | |
TOTAL CONSUMER |
|||||||||||
US |
1,214 |
1,219 |
-0.4% |
-0.4% |
- |
3,843 |
3,903 |
-1.5% |
-1.5% |
- | |
|
2,367 |
2,521 |
-6.1% |
1.8% |
-7.9% |
6,952 |
7,312 |
-4.9% |
1.4% |
-6.3% | |
WW |
|
3,740 |
-4.3% |
1.0% |
-5.3% |
|
11,215 |
-3.7% |
0.4% |
-4.1% | |
See footnotes at end of schedule |
|||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||
THIRD QUARTER |
NINE MONTHS | ||||||||||
% Change |
% Change | ||||||||||
2012 |
2011 |
Reported |
Operational (1) |
Currency |
2012 |
2011 |
Reported |
Operational (1) |
Currency | ||
PHARMACEUTICAL SEGMENT (2) (4) |
|||||||||||
IMMUNOLOGY |
|||||||||||
US |
|
1,390 |
15.1% |
15.1% |
- |
$ 4,524 |
4,350 |
4.0% |
4.0% |
- | |
|
484 |
377 |
28.4% |
37.1% |
-8.7% |
1,374 |
652 |
* |
* |
-5.7% | |
WW |
2,084 |
1,767 |
17.9% |
19.8% |
-1.9% |
5,898 |
5,002 |
17.9% |
19.2% |
-1.3% | |
REMICADE |
|||||||||||
US |
940 |
876 |
7.3% |
7.3% |
- |
2,712 |
2,500 |
8.5% |
8.5% |
- | |
US Exports (3) |
379 |
343 |
10.5% |
10.5% |
- |
1,123 |
1,360 |
-17.4% |
-17.4% |
- | |
|
272 |
189 |
43.9% |
53.2% |
-9.3% |
800 |
204 |
* |
* |
-5.7% | |
WW |
1,591 |
1,408 |
13.0% |
14.3% |
-1.3% |
4,635 |
4,064 |
14.1% |
15.1% |
-1.0% | |
SIMPONI |
|||||||||||
US |
93 |
59 |
57.6% |
57.6% |
- |
220 |
173 |
27.2% |
27.2% |
- | |
|
92 |
70 |
31.4% |
39.7% |
-8.3% |
206 |
118 |
74.6% |
83.0% |
-8.4% | |
WW |
185 |
129 |
43.4% |
47.9% |
-4.5% |
426 |
291 |
46.4% |
49.8% |
-3.4% | |
STELARA |
|||||||||||
US |
188 |
112 |
67.9% |
67.9% |
- |
469 |
317 |
47.9% |
47.9% |
- | |
|
99 |
77 |
28.6% |
39.5% |
-10.9% |
287 |
214 |
34.1% |
43.3% |
-9.2% | |
WW |
287 |
189 |
51.9% |
56.4% |
-4.5% |
756 |
531 |
42.4% |
46.1% |
-3.7% | |
OTHER IMMUNOLOGY |
|||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- | |
|
21 |
41 |
-48.8% |
-46.6% |
-2.2% |
81 |
116 |
-30.2% |
-27.2% |
-3.0% | |
WW |
21 |
41 |
-48.8% |
-46.6% |
-2.2% |
81 |
116 |
-30.2% |
-27.2% |
-3.0% | |
INFECTIOUS DISEASES |
|||||||||||
US |
259 |
216 |
19.9% |
19.9% |
- |
738 |
1,191 |
-38.0% |
-38.0% |
- | |
|
536 |
498 |
7.6% |
18.0% |
-10.4% |
1,600 |
1,282 |
24.8% |
34.1% |
-9.3% | |
WW |
795 |
714 |
11.3% |
18.6% |
-7.3% |
2,338 |
2,473 |
-5.5% |
-0.7% |
-4.8% | |
INTELENCE |
|||||||||||
US |
45 |
42 |
7.1% |
7.1% |
- |
130 |
118 |
10.2% |
10.2% |
- | |
|
49 |
41 |
19.5% |
32.1% |
-12.6% |
135 |
113 |
19.5% |
29.2% |
-9.7% | |
WW |
94 |
83 |
13.3% |
19.5% |
-6.2% |
265 |
231 |
14.7% |
19.4% |
-4.7% | |
LEVAQUIN/FLOXIN |
|||||||||||
US |
10 |
14 |
-28.6% |
-28.6% |
- |
35 |
585 |
-94.0% |
-94.0% |
- | |
|
10 |
11 |
-9.1% |
-4.8% |
-4.3% |
30 |
33 |
-9.1% |
-4.2% |
-4.9% | |
WW |
20 |
25 |
-20.0% |
-18.1% |
-1.9% |
65 |
618 |
-89.5% |
-89.2% |
-0.3% | |
PREZISTA |
|||||||||||
US |
181 |
132 |
37.1% |
37.1% |
- |
507 |
386 |
31.3% |
31.3% |
- | |
|
183 |
184 |
-0.5% |
9.9% |
-10.4% |
554 |
509 |
8.8% |
17.7% |
-8.9% | |
WW |
364 |
316 |
15.2% |
21.3% |
-6.1% |
1,061 |
895 |
18.5% |
23.5% |
-5.0% | |
OTHER INFECTIOUS DISEASES |
|||||||||||
US |
23 |
28 |
-17.9% |
-17.9% |
- |
66 |
102 |
-35.3% |
-35.3% |
- | |
|
294 |
262 |
12.2% |
22.6% |
-10.4% |
881 |
627 |
40.5% |
50.4% |
-9.9% | |
WW |
317 |
290 |
9.3% |
18.7% |
-9.4% |
947 |
729 |
29.9% |
38.4% |
-8.5% | |
REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||
THIRD QUARTER |
NINE MONTHS | ||||||||||
% Change |
% Change | ||||||||||
2012 |
2011 |
Reported |
Operational (1) |
Currency |
2012 |
2011 |
Reported |
Operational (1) |
Currency | ||
NEUROSCIENCE |
|||||||||||
US |
678 |
634 |
6.9% |
6.9% |
- |
2,010 |
2,006 |
0.2% |
0.2% |
- | |
|
990 |
1,050 |
-5.7% |
1.2% |
-6.9% |
3,019 |
3,203 |
-5.7% |
-0.4% |
-5.3% | |
WW |
1,668 |
1,684 |
-1.0% |
3.3% |
-4.3% |
5,029 |
5,209 |
-3.5% |
-0.2% |
-3.3% | |
CONCERTA/METHYLPHENIDATE |
|||||||||||
US |
150 |
179 |
-16.2% |
-16.2% |
- |
493 |
667 |
-26.1% |
-26.1% |
- | |
|
104 |
104 |
0.0% |
6.8% |
-6.8% |
337 |
327 |
3.1% |
9.1% |
-6.0% | |
WW |
254 |
283 |
-10.2% |
-7.7% |
-2.5% |
830 |
994 |
-16.5% |
-14.5% |
-2.0% | |
INVEGA |
|||||||||||
US |
78 |
74 |
5.4% |
5.4% |
- |
223 |
219 |
1.8% |
1.8% |
- | |
|
62 |
52 |
19.2% |
26.9% |
-7.7% |
180 |
155 |
16.1% |
21.5% |
-5.4% | |
WW |
140 |
126 |
11.1% |
14.3% |
-3.2% |
403 |
374 |
7.8% |
10.0% |
-2.2% | |
INVEGA SUSTENNA/ XEPLION |
|||||||||||
US |
130 |
85 |
52.9% |
52.9% |
- |
350 |
220 |
59.1% |
59.1% |
- | |
|
82 |
16 |
* |
* |
-8.7% |
218 |
23 |
* |
* |
-7.1% | |
WW |
212 |
101 |
* |
* |
-3.4% |
568 |
243 |
* |
* |
-2.7% | |
RISPERDAL CONSTA |
|||||||||||
US |
113 |
111 |
1.8% |
1.8% |
- |
336 |
335 |
0.3% |
0.3% |
- | |
|
238 |
279 |
-14.7% |
-7.2% |
-7.5% |
731 |
863 |
-15.3% |
-9.4% |
-5.9% | |
WW |
351 |
390 |
-10.0% |
-4.6% |
-5.4% |
1,067 |
1,198 |
-10.9% |
-6.7% |
-4.2% | |
OTHER NEUROSCIENCE |
|||||||||||
US |
207 |
185 |
11.9% |
11.9% |
- |
608 |
565 |
7.6% |
7.6% |
- | |
|
504 |
599 |
-15.9% |
-10.3% |
-5.6% |
1,553 |
1,835 |
-15.4% |
-11.3% |
-4.1% | |
WW |
711 |
784 |
-9.3% |
-5.0% |
-4.3% |
2,161 |
2,400 |
-10.0% |
-6.9% |
-3.1% | |
ONCOLOGY |
|||||||||||
US |
145 |
79 |
83.5% |
83.5% |
- |
371 |
236 |
57.2% |
57.2% |
- | |
|
483 |
415 |
16.4% |
27.3% |
-10.9% |
1,439 |
1,249 |
15.2% |
23.6% |
-8.4% | |
WW |
628 |
494 |
27.1% |
36.2% |
-9.1% |
1,810 |
1,485 |
21.9% |
29.0% |
-7.1% | |
DOXIL/CAELYX |
|||||||||||
US |
9 |
10 |
-10.0% |
-10.0% |
- |
22 |
130 |
-83.1% |
-83.1% |
- | |
|
7 |
76 |
-90.8% |
-89.6% |
-1.2% |
31 |
233 |
-86.7% |
-85.4% |
-1.3% | |
WW |
16 |
86 |
-81.4% |
-80.4% |
-1.0% |
53 |
363 |
-85.4% |
-84.6% |
-0.8% | |
VELCADE |
|||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- | |
|
327 |
295 |
10.8% |
20.7% |
-9.9% |
998 |
922 |
8.2% |
15.7% |
-7.5% | |
WW |
327 |
295 |
10.8% |
20.7% |
-9.9% |
998 |
922 |
8.2% |
15.7% |
-7.5% | |
ZYTIGA |
|||||||||||
US |
136 |
69 |
97.1% |
97.1% |
- |
349 |
106 |
* |
* |
- | |
|
129 |
26 |
* |
* |
-10.7% |
348 |
43 |
* |
* |
-8.5% | |
WW |
265 |
95 |
* |
* |
-5.2% |
697 |
149 |
* |
* |
-4.2% | |
OTHER ONCOLOGY |
|||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- | |
|
20 |
18 |
11.1% |
18.8% |
-7.7% |
62 |
51 |
21.6% |
28.1% |
-6.5% | |
WW |
20 |
18 |
11.1% |
18.8% |
-7.7% |
62 |
51 |
21.6% |
28.1% |
-6.5% | |
REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||
THIRD QUARTER |
NINE MONTHS | ||||||||||
% Change |
% Change | ||||||||||
2012 |
2011 |
|